Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: NLRP12

Gene summary for NLRP12

Gene summary.

Gene information	Species	Human
	Gene symbol	NLRP12
	Gene ID	91662
	Gene name	NLR family pyrin domain containing 12
	Gene Alias	CLR19.3
	Cytomap	19q13.42
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	P59046

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
91662	NLRP12	HCC1	Human	Liver	HCC	1.26e-03	7.84e-01	0.5336
91662	NLRP12	HCC2	Human	Liver	HCC	3.31e-08	1.06e+00	0.5341
91662	NLRP12	HCC5	Human	Liver	HCC	2.01e-12	7.90e-01	0.4932

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Liver		HCC: Hepatocellular carcinoma
Liver		NAFLD: Non-alcoholic fatty liver disease

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004586222	Liver	HCC	positive regulation of proteolysis	232/7958	372/18723	5.66e-15	3.98e-13	232
GO:001056322	Liver	HCC	negative regulation of phosphorus metabolic process	259/7958	442/18723	4.29e-12	1.92e-10	259
GO:004593622	Liver	HCC	negative regulation of phosphate metabolic process	258/7958	441/18723	6.00e-12	2.60e-10	258
GO:004232622	Liver	HCC	negative regulation of phosphorylation	227/7958	385/18723	3.98e-11	1.52e-09	227
GO:000193322	Liver	HCC	negative regulation of protein phosphorylation	196/7958	342/18723	1.95e-08	4.63e-07	196
GO:004328112	Liver	HCC	regulation of cysteine-type endopeptidase activity involved in apoptotic process	125/7958	209/18723	3.12e-07	5.42e-06	125
GO:200011612	Liver	HCC	regulation of cysteine-type endopeptidase activity	137/7958	235/18723	6.91e-07	1.08e-05	137
GO:005254722	Liver	HCC	regulation of peptidase activity	247/7958	461/18723	8.28e-07	1.27e-05	247
GO:005254822	Liver	HCC	regulation of endopeptidase activity	230/7958	432/18723	3.58e-06	4.68e-05	230
GO:000724912	Liver	HCC	I-kappaB kinase/NF-kappaB signaling	156/7958	281/18723	6.66e-06	8.00e-05	156
GO:004312212	Liver	HCC	regulation of I-kappaB kinase/NF-kappaB signaling	138/7958	249/18723	2.47e-05	2.58e-04	138
GO:001095212	Liver	HCC	positive regulation of peptidase activity	110/7958	197/18723	1.04e-04	8.98e-04	110
GO:00467775	Liver	HCC	protein autophosphorylation	123/7958	227/18723	2.40e-04	1.80e-03	123
GO:00434097	Liver	HCC	negative regulation of MAPK cascade	98/7958	180/18723	7.88e-04	4.74e-03	98
GO:00510902	Liver	HCC	regulation of DNA-binding transcription factor activity	220/7958	440/18723	8.04e-04	4.82e-03	220
GO:001095012	Liver	HCC	positive regulation of endopeptidase activity	96/7958	179/18723	1.68e-03	8.79e-03	96
GO:19012242	Liver	HCC	positive regulation of NIK/NF-kappaB signaling	41/7958	69/18723	3.38e-03	1.54e-02	41
GO:00380611	Liver	HCC	NIK/NF-kappaB signaling	77/7958	143/18723	3.98e-03	1.76e-02	77
GO:004328012	Liver	HCC	positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	70/7958	129/18723	4.58e-03	1.97e-02	70
GO:200105612	Liver	HCC	positive regulation of cysteine-type endopeptidase activity	79/7958	148/18723	4.82e-03	2.03e-02	79

Page: 1 2

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

NLRP12

SNV

Missense_Mutation

novel

c.625N>T

p.Pro209Ser

p.P209S

P59046

protein_coding

tolerated(0.09)

probably_damaging(0.982)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

NLRP12

SNV

Missense_Mutation

rs766308091

c.550G>A

p.Ala184Thr

p.A184T

P59046

protein_coding

tolerated(0.25)

benign(0.019)

TCGA-A1-A0SO-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

NLRP12

SNV

Missense_Mutation

c.1903N>T

p.Val635Leu

p.V635L

P59046

protein_coding

tolerated(0.27)

benign(0.382)

TCGA-A2-A0CW-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

NLRP12

SNV

Missense_Mutation

novel

c.2258N>A

p.Cys753Tyr

p.C753Y

P59046

protein_coding

deleterious(0)

probably_damaging(0.99)

TCGA-A2-A4RW-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

NLRP12

SNV

Missense_Mutation

novel

c.253N>A

p.Leu85Met

p.L85M

P59046

protein_coding

deleterious(0.01)

probably_damaging(1)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

NLRP12

SNV

Missense_Mutation

novel

c.2029N>T

p.Arg677Cys

p.R677C

P59046

protein_coding

deleterious(0.04)

benign(0.291)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

NLRP12

SNV

Missense_Mutation

rs764354581

c.2185N>T

p.Arg729Trp

p.R729W

P59046

protein_coding

tolerated(0.19)

benign(0.073)

TCGA-AN-A0AK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

NLRP12

SNV

Missense_Mutation

rs769192403

c.3065N>A

p.Arg1022Gln

p.R1022Q

P59046

protein_coding

tolerated(0.08)

possibly_damaging(0.851)

TCGA-AO-A1KR-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

NLRP12

SNV

Missense_Mutation

c.2668N>A

p.Leu890Met

p.L890M

P59046

protein_coding

deleterious(0)

probably_damaging(0.995)

TCGA-AR-A24X-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

NLRP12

SNV

Missense_Mutation

c.2734C>A

p.Pro912Thr

p.P912T

P59046

protein_coding

deleterious(0.01)

possibly_damaging(0.691)

TCGA-C8-A275-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1